Autoreactivity to myeloperoxidase (MPO) causes anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), with rapidly progressive glomerulonephritis. Here, we show that a Staphylococcus aureus peptide, homologous to an immunodominant MPO T-cell epitope (MPO 409-428 ), can induce anti-MPO autoimmunity. The peptide (6PGD 391-410 ) is part of a plasmid-encoded 6-phosphogluconate dehydrogenase found in some S. aureus strains. It induces anti-MPO T-cell autoimmunity and MPO-ANCA in mice, whereas related sequences do not. Mice immunized with 6PGD 391-410 , or with S. aureus containing a plasmid expressing 6PGD 391-410 , develop glomerulonephritis when MPO is deposited in glomeruli. The peptide induces anti-MPO autoreactivity in the context of three MHC class II allomorphs. Furthermore, we show that 6PGD 391-410 is immunogenic in humans, as healthy human and AAV patient sera contain anti-6PGD and anti-6PGD 391-410 antibodies. Therefore, our results support the idea that bacterial plasmids might have a function in autoimmune disease.
L oss of tolerance to the neutrophil enzyme myeloperoxidase (MPO) leads to anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (MPO-AAV), an autoimmune disease that can affect multiple tissues but which often involves the kidney. In MPO-AAV, patients frequently develop rapidly progressive glomerulonephritis and are at risk of end-stage kidney failure 1 . The other major autoantigen known to be clinically relevant in AAV is the neutrophil serine protease, proteinase-3 (PR3). MPO-AAV and PR3-AAV, while having some differences, share similar pathogenic features. In MPO-AAV, tissue injury is induced not by autoantibodies binding to target tissues such as the kidney, but by anti-MPO autoantibodies (MPO-ANCA) that bind to and activate neutrophils causing glomerular neutrophil recruitment, degranulation, and NETosis [2] [3] [4] . These activated neutrophils are not only themselves responsible for significant tissue injury and damage, they also deposit MPO in and around glomerular capillaries 2,4-6 . Thus, MPO accumulating in glomeruli may function as an antigenic target for MPO-specific effector CD4 + and CD8 + T cells that induce a further wave of cellmediated injury 3, [6] [7] [8] [9] .
Although it is unclear how tolerance to neutrophil cytoplasmic antigens MPO and proteinase-3 (PR3) is lost and how disease is triggered 10 , like many autoimmune diseases 11 , both genetic and environmental factors are probably important 12, 13 . In particular, infection has been implicated both in clinical studies, and in in vitro and in vivo experimental work 5, [14] [15] [16] [17] . Nasal carriage of Staphylococcus aureus is associated with an increase in relapse of disease in granulomatosis with polyangiitis, characterized by loss of tolerance to PR3 (PR3-AAV) 14 . Less is known about S. aureus colonization of people with MPO-AAV. While chronic nasal carriage is uncommon in those with microscopic polyangiitis and renal limited vasculitis, usually associated with MPO-ANCA 18 , nasal colonization does occur 19 and case reports implicate S. aureus in the development of this condition [20] [21] [22] . There are several mechanisms by which infections might influence AAV; superantigens have been hypothesized to have a function 23 , and pathogen-associated molecular patterns stimulate antigen presentation, B cells, and prime neutrophils 24 . The release of autoantigens (including PR3 and MPO) by neutrophils at sites of infection might also affect the maintenance of tolerance. A further potential consequence of the uptake of neutrophil-derived autoantigens by antigen-presenting cells at sites of inflammation with innate immune system activation could be the development of molecular mimicry. As molecular mimicry can lead to T-cell receptor (TCR) cross-reactivity [25] [26] [27] [28] , a microbial mimotope presented as a peptide by MHC Class II (MHCII) might activate TCRs that also recognize PR3 or MPO-derived epitopes presented by MHCII.
Some evidence supports the involvement of molecular mimicry in the loss of tolerance to neutrophil antigens in AAV. The complementary PR3 autoantigenic sequence, implicated in loss of tolerance to PR3, shares homology with bacterial peptides, including some from S. aureus 29 . Another target neutrophil antigen, lysosomal antigen membrane protein-2 (LAMP-2), shares sequence homology with the bacterial adhesin FimH, with FimH immunization of rats inducing anti-LAMP-2 autoantibodies and glomerulonephritis 30 . However, it is not known whether molecular mimicry has any function in loss of tolerance to MPO and the resultant development of MPO-AAV.
Here, we demonstrate that molecular mimicry mechanistically contributes to the loss of tolerance to MPO in AAV. We evaluate whether microbial-derived peptides, including those from S. aureus, with sequence homology to the immunodominant MPO CD4 + T-cell epitope can induce the expansion of naive CD4 + T cells that recognize MPO, with the subsequent development of cross-reactive anti-MPO autoimmunity leading to glomerulonephritis and AAV. We identify a S. aureus peptide, 6phosphogluconate dehydrogenase (6PGD) 391-410 derived from a plasmid-encoded protein that induces cellular and humoral anti-MPO autoimmunity and experimental anti-MPO glomerulonephritis. Thus, molecular mimicry mediated by a bacterial plasmid capable of horizontal transmission represents a potential mechanism of loss of tolerance in autoimmune disease.
Results
Highly homologous peptides do not induce autoreactivity. To determine if autoreactivity to the immunodominant MPO CD4 + T-cell epitope, mouse MPO 409-428 6 , could be induced by microbial peptides, we performed a protein BLAST (blastp) search using the core 11-mer sequence of the equivalent human MPO peptide, 441 RLYQEARKIVG 451 (mouse MPO peptide sequence and numbering: 415 KLYQEARKIVG 425 ). Sequences from the Animalia kingdom (taxid:33208) and microbes not known to colonize humans were excluded. Based on the search results, we selected the four most homologous sequences (Supplementary Table 1 ) and because we have demonstrated previously that a 20-mer peptide induces stronger immunoreactivity to MPO 6 (concordant with MHCII molecules having an open ended binding groove 31 ), we synthesized 20-mers based on the four identified sequences. For example, for the Aspergillus fumigatus HEAT repeat protein 831-841 ( 831 RWYQEARKIIF 841 ) the synthesized 20-mer was 825 ISALPQRWYQEARKIIFEAA 844 .
To determine whether these sequences could induce anti-MPO autoimmunity we immunized C57BL/6 mice with individual 20mers and measured T-cell reactivity to either the immunizing peptide, MPO 409-428 , or recombinant mouse (rm)MPO using interferon-γ (IFN-γ) and interleukin (IL)-17A ELISPOTs and [ 3 H]-T proliferation assays. While some homologous sequences induced reactivity to themselves, none induced reactivity to MPO 409-428 or whole rmMPO ( Fig. 1a-f ), demonstrating that high sequence homology per se does not result in immunological cross-reactivity to MPO.
A S. aureus-derived peptide induces anti-MPO autoimmunity. As S. aureus infections can precede the development of MPO-AAV [20] [21] [22] , they are related to an overlapping form of vasculitis (PR3-AAV) 14, 29 and nasal colonization of S. aureus has been found in people with MPO-AAV 19 we identified a S. aureusderived peptide with sequence homology to human MPO 441-451 by protein BLAST. The highest scoring S. aureus-derived peptide containing the previously defined critical MPO 441-451 T-cell epitope residues (Tyr443, Arg447, Ile449 and Val450: 441 RLY-QEARKIVG 451 ) 6 was selected (BLAST MAX score of 18.0 out of 38.4 compared to human MPO 441-451 ). The identified peptide, 6PGD [397] [398] [399] [400] [401] [402] [403] [404] [405] [406] [407] [408] ( 397 TDYQEALRDVVA 408 ) was from 6phosphogluconate dehydrogenase (6PGD), an enzyme of the pentose phosphate pathway, and was first described within the plasmid pSJH101 from the clinically relevant S. aureus strain JH1 32 . To determine whether this 6PGD 397-408 sequence induced autoimmunity to MPO, we immunized C57BL/6 mice with 6PGD [391] [392] [393] [394] [395] [396] [397] [398] [399] [400] [401] [402] [403] [404] [405] [406] [407] [408] [409] [410] ( 391 YFKNIVTDYQEALRDVVATG 410 ). Mice developed reactivity to 6PGD 391-410 , as well as autoreactivity to both the immunodominant MPO CD4 + T-cell epitope, MPO 409-428 , and to rmMPO ( Fig. 2a ). MPO 409-428 -immunized mice served as a positive control. To determine if exposure to 6PGD 391-410 induces in vivo expansion of MPO-specific T cells, we immunized mice with 6PGD 391-410 then enumerated the number of MPO-specific T cells using an I-A b tetramer presenting the core mouse MPO T-cell epitope ( 415 KLY-QEARKIVG 425 ). We compared the total numbers of MPOspecific T cells from naive mice, OVA 323-339 immunized mice and MPO 409-428 immunized mice using MPO:I-A b tetramers. Cells were tetramer enriched using magnetic beads, then gated on live, CD4 + , Dump − , MPO:I-A b tetramer + cells. Compared with naive mice and with mice immunized with OVA 323-339 , mice immunized with 6PGD 391-410 exhibited a~30-fold increase in MPO:I-A b -specific CD4 + T cells ( Fig. 2b ). Thus, 6PGD 391-410 induces expansion of MPO 415-425 -specific CD4 + cells and proinflammatory autoreactivity to MPO.
Serum from 6PGD 391-410 immunized mice bound to fixed thioglycolate induced peritoneal neutrophils from C57BL/6 mice, in a perinuclear ANCA (pANCA) fashion ( Fig. 3a ) but not to MPO deficient (Mpo −/− ) mouse neutrophils, and to whole native mouse (nm)MPO by enzyme-linked immune sorbent assay (ELISA) (Fig. 3b ), findings that meet the diagnostic criteria for MPO-ANCA positivity in humans 33 . Furthermore, purified serum IgG bound to the clinically relevant human linear B-cell epitope MPO 447-459 ( Fig. 3c ) 34 . To demonstrate antibody crossreactivity between 6PGD 391-410 and MPO 409-428 , we performed an inhibition ELISA. Purified serum IgG from 6PGD 391-410 immunized mice was pre-incubated with 6PGD 391-410 , then used to detect anti-MPO 409-428 IgG by ELISA. Serum IgG from S. aureus 6PGD 391-410 immunized mice pre-incubated with S. aureus 6PGD 391-410 had lower antibody titers compared with serum IgG pre-incubated with blocking buffer only ( Fig. 3d) . These cross-reacting antibodies were functionally active, as serum IgG from 6PGD 391-410 immunized mice induced reactive oxygen species production from LPS-primed bone marrow mouse neutrophils in vitro as detected by the conversion of dihydrorhodamine to rhodamine 123 ( Fig. 3e ). In vivo, passive transfer of this IgG fraction induced acute neutrophil glomerular recruitment in LPS-primed C57BL/6 mice, albeit at a low level ( Fig. 3f ). These data demonstrate that antibodies specific for S. aureus 6PGD 391-410 cross-react with MPO 409-428 and that the S. aureus-derived peptide induces both anti-MPO T-cell autoreactivity and biologically active MPO-ANCA.
To identify if the S. aureus-derived 6PGD protein is immunoreactive in healthy humans and in AAV patients, we measured IgG antibodies specific for the S. aureus pSJH101 6PGD protein by ELISA in sera from a Groningen cohort of healthy human subjects, 31 MPO-AAV patients and 30 PR3-AAV patients. We found detectable levels of S. aureus 6PGD-specific IgG in all three groups ( Fig. 4a ) implying that S. aureus pSJH101 6PGD is an immunogenic protein in humans. Furthermore, sera exhibited reactivity to the pSJH101 JH1 S. aureus 6PGD 391-410 sequence by ELISA ( Fig. 4b ), demonstrating the immunogenicity of this sequence in humans. There were no significant differences in antibody titers between groups. To identify whether 6PGD 391-410 can cross-react with anti-MPO antibodies in acute MPO-AAV, a Monash cohort of 15 patients with acute, active MPO-AAV was assessed (Supplementary Table 2 ). Purified IgG from these patients was assessed by inhibition ELISA by preincubation with 6PGD 391-410 , then antibodies to human MPO 435-454 (the homologous sequence to mouse MPO 409-428 ) were examined by ELISA. Of the 15 patients, five showed a significant reduction in anti-human MPO 435-454 titers after incubation with 6PGD 391-410 ( Fig. 4c ). S. aureus clonal specificity for the 6PGD 397-408 mimotope. This particular 6PGD 397-408 sequence is unique to the Staphylococcus genus. S. aureus makes up the majority of publicly available staphylococcal genomes and the 6PGD 397-408 sequence of interest predominates in a clinically relevant S. aureus clonal complex (CC) known as CC5, to which the JH-1 strain belongs 35, 36 . We assessed the multi-locus sequence type of 136 of the 143 sequenced S. aureus strains containing the 6PGD 397-408 mimic sequence and found that 115 (85% of those typed) of them were CC5. S. aureus CC5 strains have been described in Asia, America, Australia, Africa, and Europe [35] [36] [37] . There are 2544 publicly available CC5 S. aureus genomes, indicating that~5% of sequenced CC5 strains contain the 6PGD 397-408 sequence. To assess the specificity of the CC5 related 6PGD 397-408 sequence in inducing cross-reactivity to MPO, we selected the four 6PGD variants most homologous to the pSJH101-derived S. aureus sequence ( Supplementary Table 3 ), commonly found in sequenced S. aureus genomes. While each 6PGD peptide induced T-cell reactivity to itself, remarkably, none induced cross-reactive anti-MPO T-cell responses ( Fig. 5a-f ). Mice immunized with these variants did not develop MPO-ANCA, either by indirect immunofluorescence on mouse neutrophils (Fig. 6a ) or by ELISA ( Fig. 6b ). When we measured anti-MPO 447-459 -specific IgG in purified serum IgG, detectable levels of IgG were found only in Variant 1, but not in any of the other 6PGD peptide variants ( Fig. 6c ). Therefore, while the variant sequences of this S. aureus 6PGD-derived peptide are immunogenic, it is only the JH1, pSJH101 6PGD 397-408 sequence that induces anti-MPO T-cell responses and MPO-ANCA. To exclude the possibility that the orthologous, but dissimilar mammalian 6PGD sequence (6PGD 394-413 ) itself represented a new autoimmune target, mice were immunized with mouse 6PGD 394-413 . This sequence did not induce cross-reactivity to MPO 409-428 or whole MPO (Supplementary Fig. 1 ).
Immunization with 6PGD 391-410 leads to anti-MPO nephritis.
To determine if the loss of tolerance to MPO induced by S. aureus JH1-derived pSJH101 6PGD 391-410 could result in anti-MPO glomerulonephritis, we used our established model of T-cellmediated anti-MPO glomerulonephritis 9, 38 . In this model, C57BL/6 mice immunized with MPO lose tolerance to MPO but do not develop ANCA of sufficient pathogenicity to induce glomerulonephritis. Therefore, MPO is deposited within the glomerulus via neutrophils transiently recruited by injection of low dose of heterologous anti-mouse basement membrane globulin. In this context, effector MPO-specific T cells recognize MPO peptides and mediate glomerular injury 6, 8, 9 . MPO-immunized mice develop glomerulonephritis with pathological albuminuria and segmental glomerular necrosis. Using this protocol, mice immunized with the S. aureus JH1-derived pSJH101 6PGD 391-410 peptide developed glomerulonephritis of similar severity to MPO- immunized mice with elevated albuminuria, glomerular segmental necrosis, and inflammatory cell infiltrates ( Fig. 7) . Furthermore, the pSJH101 6PGD 391-410 immunized mice developed MPO-ANCA and T-cell reactivity to rmMPO, detected by measuring dermal delayed type hypersensitivity to rmMPO. A further group of mice was immunized with the Variant 3 peptide of 6PGD 391-410 (Supplementary Table 3 ), chosen because, of the four variants it was found most frequently in sequenced strains of S. aureus. As hypothesized, mice immunized with Variant 3 of 6PGD 391-410 did not develop disease ( Fig. 7) , demonstrating the relative specificity of the JH1 pSJH101 6PGD 391-410 sequence in nephritogenic anti-MPO autoimmunity.
S. aureus JH1 with pSJH101 immunization leads to nephritis.
To address a specific role for the S. aureus pSJH101 plasmidderived 6PGD 391-410 sequence in anti-MPO autoimmunity and glomerulonephritis in the context of whole bacteria, we immunized mice with either heat-killed S. aureus JH1 strain containing the pSJH101 plasmid or heat-killed JH1 that had been cured of the pSJH101 plasmid ( Supplementary Fig. 2a ) and induced the same model of glomerulonephritis. Compared to mice immunized with cured heat-killed S. aureus JH1, mice immunized with S. aureus JH1 containing pSJH101 developed glomerulonephritis with pathological albuminuria, glomerular focal, and segmental necrosis and infiltrates of CD4 + T cells, CD8 + T cells and macrophages ( Fig. 8 ). Mice immunized with S. aureus JH1 containing the pSJH101 plasmid also developed MPO-ANCA and MPO-specific secretion of IFN-γ and tumor necrosis factor (TNF) measured in supernatants of cultured splenocytes restimulated with rmMPO ( Fig. 8 ). Therefore, the pSJH101 plasmid containing the cross-reactive S. aureus 6PGD sequence is required for anti-MPO cross-reactivity and disease.
Plasmid and strain independent 6PGD induced anti-MPO immunity. To determine if it is the specific 6PGD sequence that causes disease independent of other proteins encoded by pSJH101 and independent of the S. aureus strain, we cloned 6PGD containing the mimic 397 TDYQEALRDVVA 408 sequence into the inducible vector pALC2073 (that does not otherwise express 6PGD) to create pALC2073-6PGD. We then transformed a common laboratory S. aureus strain (RN4220 39 , that contains neither plasmids nor 6PGD 397 TDYQEALRDVVA 408 ) with either pALC2073-6PGD or pALC2073 alone. Enhanced expression of 6PGD was confirmed after the induction of anhydrotetracycline ( Supplementary Fig. 2b ). We immunized mice with heat-killed S. aureus RN4220 expressing 6PGD or heat-killed S. aureus RN4220 with pALC2073 alone, and disease was again triggered by low- Mice immunized with S. aureus RN4220 with pALC2073 containing 6PGD developed elevated albuminuria, glomerular segmental necrosis, increases in glomerular CD4 + T cells, CD8 + T cells and macrophages, as well as MPO-specific IgG and MPOspecific splenocyte secretion of IFN-γ and TNF ( Fig. 9 ). Mice immunized with RN4220 with pALC2073 alone were similar to OVA-immunized mice ( Fig. 9 ). Therefore, it is the 6PGD sequence 391 YFKNIVTDYQEALRDVVATG 410 itself that induces anti-MPO pathogenic autoreactivity, independent of the S. aureus strain or plasmid used.
MHCII promiscuous induction of anti-MPO cross-reactivity.
The dominant MPO T-cell epitope MPO 409-428 , defined in I-A b expressing C57BL/6 mice is MHCII promiscuous, as MPO 409-428 also induces autoreactivity in BALB/c mice expressing I-A d /E d and in humanized HLA transgenic mice expressing HLA-DR15 6 .
Here, we show that the core MPO T-cell epitope, MPO 415-425 , previously defined in C57BL/6 mice is the same in both BALB/c and HLA-DR15 mice ( Supplementary Fig. 3a, b ) and the critical amino acids, defined by alanine substitution, are similar (Supplementary Fig. 3c ). To determine if the pSJH101-derived 6PGD 391-410 induces anti-MPO cross-reactivity in mice expressing different MHCII molecules, we immunized either BALB/c or humanized HLA-DR15 transgenic mice with 6PGD 391-410 and measured T-cell reactivity, by [ 3 H]-T proliferation assays and ELISPOT for IFN-γ and IL-17A, to 6PGD 391-410 itself and crossreactivity to MPO 409-428 and to rmMPO. We found that both BALB/c and HLA-DR15 transgenic mice developed immunoreactivity to 6PGD 391-410 , and cross-reactivity both to MPO 409-428 and to rmMPO ( Fig. 10a, b ), supporting the notion that pSJH101 6PGD 391-410 sequence can be effectively presented and induce anti-MPO cross-reactivity by a variety of MHCII alleles.
Discussion
Although we know that a critical step in the development of autoimmune disease is the activation of pro-inflammatory T cells that react with self-antigens, the steps that precipitate the development and activation of these pathogenic T cells are still unclear.
Recently, we have shown that peptide register is a key determinant of the phenotype of the autoreactive T-cell repertoire 40 . While molecular mimicry is often flagged as a potential trigger for the activation of existing autoreactive pro-inflammatory T cells, fewer studies have formally demonstrated microbial-self-peptide cross-reactivity, which is often attributable to the lack of understanding of the self-antigen that precipitates disease [26] [27] [28] . The current studies not only identify a mimotope peptide, pSJH101 6PGD 391-410 that induces anti-MPO T and B-cell autoimmunity, they also highlight both the sensitivity of such mimicry, as very similar sequences to the mimic peptide were unable to induce cross-reactivity. Importantly our studies demonstrate the potential for mimicry to be induced by a plasmid-encoded microbial sequence, identifying a potential new role for bacterial plasmids in the pathogenesis of disease. We and others have identified a "molecular hotspot" within MPO where an immunodominant T-cell epitope and a diseaseassociated antibody epitope overlap 6, 8, 34 . PR3-AAV is classically associated with S.aureus 14, 15 and reports also implicate S. aureus infections in MPO-AAV [19] [20] [21] [22] . However, despite the presence of neutrophil-derived MPO at sites of infection in a potentially "dangerous" immunological context, the links between the loss of tolerance to MPO and microbial-derived peptides are unclear. Using a standard and unbiased approach of searching microbial proteomes in silico for peptide sequences with the highest sequence similarities to MPO 441-451 we identified a number of microbial peptides from human pathogens, but experimentally these sequences did not induce anti-MPO cross-reactivity. However, when S. aureus-derived peptides sharing the critical amino acid residues were examined, we identified a plasmidderived peptide that induces anti-MPO immunoreactivity in the context of several different MHCII molecules and that is immunogenic in humans. This MPO mimotope, pSJH101 6PGD 391-410 , is overall less homologous than the other non-cross-reactive microbial-derived peptides tested, demonstrating that sequence similarity itself is not necessarily a predictor of molecular mimicry 41 . Instead, specific structural determinants may be more of a contributory factor that leads to cross-reactivity 42 . Our experiments, using similar 6PGD 391-410 sequences from a range of S. aureus strains demonstrated that even single amino-acid substitutions were sufficient to abrogate anti-MPO cross-reactivity. For example, in Variant 1, a substitution from glutamic acid (E) to the smaller aspartic acid (D), and in Variant 2, a substitution from the negatively charged aspartic acid (D) to the uncharged asparagine (N), prevented the induction of anti-MPO cross-reactivity, highlighting the exquisite sensitivity of TCRs to specific peptide structures.
Using ex vivo restimulation assays, as well as MPO:I-A b tetramers, we have demonstrated that pSJH101 6PGD 391-410 can induce anti-MPO CD4 + T-cell cross-reactivity. Furthermore, in addition to cellular immunity, the 6PGD 391-410 peptide also induces autoantibodies to whole nmMPO, to the diseaseassociated linear MPO peptide and to an overlapping linear MPO peptide. The 6PGD 391-410 mimotope inhibited autoantibody binding to this peptide in mice via a solid phase competitive ELISA. 6PGD 391-410 also inhibited binding to human MPO 435-454 (equivalent to mouse MPO 409-428 ) in 5/15 (33%) of humans with acute MPO-AAV. Collectively, these data confirm a functional interaction between these overlapping epitopes. Thus, the pSJH101 6PGD 391-410 peptide cross reacts with an MPO T-cell epitope, but it is also likely to be relevant to these linked B-cell epitopes. While it is possible that antibodies to 6PGD 391-410 serve as effectors, as for example in the seminal studies of Kaplan and Meyesarian, and others for streptococcal antigens and acute rheumatic fever 43, 44 , we suggest that this type of direct reactivity at an effector level is less likely in MPO-AAV. Cross-reactivity at a B cell/B-cell receptor level is more likely to be relevant to the promotion of B-cell autoreactivity via binding of 6PGD 391-410 to the B-cell receptor of potentially autoreactive B cells. This would promote autoreactive anti-MPO B-cell activation by autoreactive CD4 + T cells reacting to the same peptide. In this context, the relative affinities of 6PGD 391-410 and MPO 409-428 (in humans MPO 435-454 ) to anti-MPO antibodies and whether 100% inhibition occurs, is unlikely to be of critical importance. Furthermore, 6PGD 391-410 alone is unlikely to have a measurable effect on the There have been several studies of nasal carriage of S. aureus in people with PR3-AAV, due in part to sinonasal disease being common in PR3-AAV 14, 15, 19 . However, the potential relationship between S. aureus and MPO-AAV has been largely unexplored, though colonization with S. aureus does occur in patients with this disease 19 . Most S. aureus strains known to carry the nephritogenic 6PGD 391-410 sequence belong to the CC5 clonal complex 19 . In S. aureus carriers with established MPO-AAV, 11% of isolates were CC5 (healthy controls 5%, PR3-AAV 15%) 19 . CC5 is a globally distributed clonal complex of S. aureus found in both community and hospital settings 35, 36, 45 .
It is not yet known in humans whether carriage or infection of S. aureus strains containing the cross-reactive 6PGD 391-410 sequence promotes the induction of MPO-AAV or precipitates disease relapse. The conditions for 6PGD 391-410 recognition to induce anti-MPO T-cell cross-reactivity may include S. aureus infection, intermittent colonization or chronic colonization. Furthermore, while nasal swabs are the most common way of screening for S. aureus, carriage also occurs on the skin, and in the throat, vagina, anus, and lower gastrointestinal tract [46] [47] [48] . It is unlikely that the 6PGD 391-410 mimotope is the sole factor that determines loss of tolerance to MPO, given the frequency of antibodies to the 6PGD protein and peptide, and the multiple genetic and environmental factors that contribute to the development of MPO-AAV.
Although our data do not conclusively prove a role for 6PGD 391-410 , they suggest that exposure to certain S. aureus strains may be a precipitating factor in the loss of tolerance to MPO and the development of MPO-AAV. Our data also demonstrates that plasmids, acting as mobile genetic elements, may transfer a tendency to autoreactivity. The transfer of antibiotic resistance via plasmids is well known. However, the horizontal gene transfer of the cross-reactive 6PGD that we emulated by transforming S. aureus RN4220 with pALC2073-6PGD demonstrates that plasmids harboring cross-reactive peptide sequences can induce loss of tolerance. In conclusion, our findings identify pSJH101 6PGD 391-410 as an MPO cross-reactive mimotope peptide. 6PGD 391-410 is part of a protein that is immunogenic in humans, can induce loss of tolerance to MPO and experimental anti-MPO glomerulonephritis and MPO-AAV. This sequence is derived from a plasmid found in only some strains of S. aureus, implicating plasmid-derived antigens in the loss of tolerance to self-antigens. Supplementary Table 3 . Immunizations to induce CD4 + T-cell responses were performed with 20-mers containing the core 11 amino acids because MHC class II molecules have open-ended binding pockets and additional amino acids on either side enhances immunoreactivity 6 . MPO was produced using a baculovirus system 53 and OVA was purchased (Sigma-Aldrich). Recombinant S. aureus pSJH101 6PGD (Genbank ID: CP000737.1) (GeneArt®, ThermoFisher Scientific) was produced using the Champion pET101 Directional TOPO Expression Kit with BL21 Star (DE3) One Shot chemically competent E. Coli (ThermoFisher Scientific). Expression was confirmed by using anti-V5 monoclonal antibodies by western blotting and purified by 6xHis tag elution using nickel resins (Promega). Plasmids and Staphylococcus aureus strains. The pSJH101 plasmid was found within a clinical isolate of S. aureus JH1 (also known as strain A8090) 56 . To cure the pSJH101 plasmid from S. aureus JH1, cells were cultured with 0.004% SDS at 45°C for 24 h 57 . To confirm the presence or absence of the pSJH101 plasmid containing 6PGD, PCR was performed on cell lysates using primers specific for: cls2, forward primer 5′ GCAAGGTACCATGATAGAGTTATTATCCATTGC 3′, reverse primer 5′ GCAAGAGCTCTTAGTGGTGATGGTGATGATGTAAGATAGGTGACAATA ATTGTG 3′; pSJH101, forward primer 5′ CATTGGCGAATCAACAACAC 3′, reverse primer 5′ ACTCCACTTTTGGGGGAACT 3′; and the pSJH101-derived 6PGD, which do not amplify the more common 6PGD (Variant 3) present in the chromosomal DNA of JH1: forward primer 5′TCATCATCTAACAGCGGAAGT3′ and reverse primer 5′ ACCCCGTAAAATTTTGTTGAT 3′. The 6PGD sequence (derived from pSJH101) was cloned into the tetracycline inducible pALC2073 plasmid 58 . S. aureus RN4220, which contains neither plasmids nor the 6PGD 397 TDYQEALRDVVA 408 sequence, was transformed by electroporation with either pALC2073 containing 6PGD or pALC2073 without 6PGD 59, 60 . To confirm expression of 6PGD we performed PCR on cDNA from cultured S. aureus RN4220 containing pALC2073 with 6PGD with or without tetracycline, S. aureus RN4220 containing pALC2073 without 6PGD cultured with tetracycline. As a control for specificity, we performed PCR using chromosomal DNA of S. aureus RN4220. The primers we used were: forward primer 5′ TCATCA TCTAACAGCGGAAGT 3′ and reverse primer 5′ ACCCCGTAAAATTTTG TTGAT 3′ chromosomal DNA of chromosomal DNA of S. aureus RN4220. The primers we used were: forward primer 5′ TCATCATCTAACAGCGGAAGT 3′ and reverse primer 5′ ACCCCGTAAAATTTTGTTGAT 3′. For in silico multi-locus sequence typing (MLST), the software mlst was used to identify the sequence types (STs) after scanning the genomes of interest 61 , then STs were grouped into CC in which each ST in the CC shares at least six identical alleles of the seven loci with at least one other member of the group 62 . Induction and assessment of T-cell responses. Mice were immunized with 10 µg of peptide emulsified in Freund's complete adjuvant (FCA) subcutaneously at the base of the tail. Ten days later, draining lymph node cells were isolated and cultured in [ 3 H]-T proliferation assays and/or IFN-γ and IL-17A ELISPOTs. Lymph node cells were cultured in triplicate in supplemented RPMI media (10% vol/vol FCS, 2 mM L-glutamine, 100 U mL −1 penicillin, 0.1 mg mL −1 streptomycin, 50 µM 2-Mercaptoethanol) at 5 × 10 5 cells per well in the presence or absence of peptide (10 µg ml −1 ) or whole protein antigen (10 µg ml −1 ) in a humidified incubator at 37°C , 5% CO 2 for 72 h in proliferation assays and 18 h in ELISPOTs. In proliferation assays, [ 3 H]-thymidine was added during the last 16 h of culture and results expressed as a stimulation index. For IFN-γ and IL-17A ELISPOTs (eBioscience, anti-IFN-γ antibodies 551216, 1:250 and 554410, 1:250; anti-IL-17A antibodies 555068, 1:1000 and 555067, 1:1000), spots were developed according to the manufacturer's protocol and results expressed as the mean number of spots minus baseline (media alone). To determine the in vivo expansion of MPO-specific cells, mice were first immunized with 10 μg of peptide emulsified in FCA subcutaneously at the base of the tail, then, 7 days later, the inguinal, axillary, brachial, cervical, mesenteric, and periaortic lymph nodes and spleen were harvested. Following, tetramer-based magnetic enrichment 63, 64 , cells were incubated with Live/ Dead fixable Near IR Dead Cell Stain (Thermo Scientific) then stained with antimouse CD4-Pacific Blue (BioLegend, 100531, 1:400) and "dump" antibodies antimouse CD11c (all BioLegend, 117311, 1:100), CD11b (101217, 1:100), F4/80 (123120, 1:100), CD8a (100723, 1:100), B220-Alexa Fluor 488 (103225, 1:100). The MPO:I-A b tetramer + gate was set based on the CD4 + live lymphocyte population (see Supplementary Fig. 4 for gating strategy). PAS-stained kidney sections Fig. 9 Experimental anti-MPO glomerulonephritis in mice injected with S. aureus RN4220 containing pALC2073. C57BL/6 mice were immunized with either OVA (negative control, n = 4), MPO (positive control, n = 3), S. aureus RN4220 containing pALC2073 with 6PGD (n = 6) or S. aureus RN4220 containing pALC2073 alone, without 6PGD (n = 6). OVA and MPO were emulsified in Freund's complete adjuvant; S. aureus RN4220 containing pALC2073 with or without 6PGD were emulsified in Titermax. MPO was deposited in glomeruli using heterologous low-dose anti-basement membrane globulin. Renal injury was measured by albuminuria, and by glomerular segmental necrosis on periodic acid-Schiff (PAS) stained kidney sections. Photomicrographs depict glomeruli from mice immunized with either S .aureus RN4220 containing pALC2073 with 6PGD or RN4220 containing pALC2073 without 6PGD. Inflammatory cells within glomeruli were enumerated and expressed as cells per glomerular cross section (gcs Human sera were tested for reactivity to 6PGD (HS n = 23, MPO-AAV n = 31 and PR3-AAV n = 30) and to S. aureus pSJH101 6PGD 391-410 (HS n = 14, MPO-AAV n = 26) and PR3-AAV patients (n = 24) by ELISA. The HS groups were different between assays, and not all samples assayed for whole 6PGD were available for the S. aureus pSJH101 6PGD 391-410 assay. ELISA plates (NUNC Maxisorp, Thermo Fisher Scientific, Breda, The Netherlands) were coated with 100 μl of 5 μg ml −1 recombinant S. aureus pSJH101 6PGD or 10 μg ml −1 S. aureus pSJH101 6PGD 391-410 peptide diluted in 0.1 M carbonate-bicarbonate buffer (pH 9.6) overnight. Plates were washed with PBS pH 7.4 with 0.05% Tween-20 and incubated for 1 h at room temperature (RT) with 200 μl 2% bovine serum albumin (BSA)/PBS per well to prevent non-specific binding. Next, plates were incubated with 100 μl serum samples (1:50 in PBS 1% BSA, 0.05% Tween-20, 2 h at RT). After washing, plates were incubated with alkaline phosphatase goat anti-human IgG (Sigma, St. Louis, USA, A-5403, 1:1000) for one hour at RT and p-nitrophenylphosphate disodium (Sigma) was used as a substrate. Absorbance was measured at 405 nm. For inhibition ELISA, IgG purified from sera or plasma exchange effluent (50 μg ml −1 ) was first pre-incubated with S. aureus pSJH101-derived 6PGD 391-410 on a 96-well ELISA plate (coating concentration 10 μg ml −1 ), then transferred to a human MPO 435-454 coated (10 μg ml −1 ) 96-well ELISA plate.
Generation of MPO:I-
Induction of mouse anti-MPO glomerulonephritis. C57BL/6 mice were immunized subcutaneously at the tail base with either 20 µg of OVA (control antigen), 20 µg of rmMPO, 100 µg of S. aureus pSJH101 6PGD 391-410 , 100 µg of S. aureus Variant 3 6PGD 391-410 , 10 mg of heat-killed S. aureus JH1, 10 mg of cured heatkilled S. aureus JH1, 10 mg of heat-killed S. aureus RN4220 transformed with pALC2073 with 6PGD or 10 mg of heat-killed S. aureus RN4220 transformed with pALC2073 without 6PGD. Proteins and peptides were injected first emulsified in Freund's Complete Adjuvant (FCA) (day 0), then 7 days later emulsified in Freund's Incomplete Adjuvant (FIA) (day 7). S. aureus strains were emulsified in Titermax (Sigma-Aldrich) and injected on days 0 and 7. On day 16, MPO was deposited in glomeruli by recruiting neutrophils using a low dose of intravenously injected heterologous anti-mouse basement membrane antibodies 9, 38, 65 . Experiments ended on day 20. Albuminuria was determined by ELISA (Bethyl Laboratories, E90-134) on urine collected 24 h before the end of experiment. Segmental glomerular necrosis was assessed on formalin fixed, paraffin embedded, 3 µm thick, PAS-stained sections and defined as the accumulation of PAS-positive material with hypocellularity.
CD4 + T cells, CD8 + T cells, macrophages, and neutrophils were detected by immunoperoxidase staining frozen kidney sections. A minimum of 20 consecutively viewed glomeruli were assessed per animal. The primary mAbs used were clones GK1.5 (anti-mouse CD4; American Type Culture Collection, 20 μg ml −1 ), 53-6.7 (anti-CD8a; BioXcell, 10 μg ml −1 ), FA/11 (macrophages, anti-mouse CD68; from GL Koch, MRC Laboratory of Molecular Biology, Cambridge, United Kingdom, 10 μg ml −1 ), and RB6-8C5 (neutrophils, anti-Gr-1, 2.5 μg ml −1 ). MPOspecific delayed type hypersensitivity was measured by intradermal injection of 10 μg of rmMPO, diluted in PBS, into the left plantar footpad. The same volume of PBS was administered into the contralateral footpad. DTH was quantified 24 h later by measurement of the difference in footpad thickness. IFN-γ, TNF, IL-17A, and IL-6 in rmMPO stimulated splenocyte cultures was measured by cytometric bead array (BD Biosciences, 560485).
Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Source data for Figs. 1, 2 , 3b-f, 4, 5b-c, 6-10, and Supplementary Figs. 1-3 are presented in the Source Data file. Other data that support the findings of this study are available from the corresponding author upon reasonable request. 
